期刊文献+

恶性与交界性胃肠道间质瘤差异表达microRNA的初步筛选 被引量:5

Screening of differentially expressed microRNAs in borderline and malignant gastrointestinal stromal tumors
原文传递
导出
摘要 目的胃肠道间质瘤(GIST)包括良性、交界性及高度恶性的广谱生物学行为,通过初步筛选恶性GIST与交界性GIST差异表达的microRNA(miRNA),探讨miRNA在GIST恶性转化过程中的潜在作用。方法收集6例胃GIST标本,恶性组3例,交界组3例。用Agilent人miRNA寡核苷酸基因芯片V3(955个已知的miRNA)进行检测。选取恶性组与交界组之间4个差异表达最明显的miRNA,利用荧光即时定量PCR技术,在22个样本中进行验证。结果恶性组与交界组相比较,相差倍数2倍以上且P值小于0.05的差异表达miRNA有14个,上调的有5个,下调的有9个。其中差异最明显,即P值最小的4个miRNA,分别为miR-221、miR-135b、miR-675*、miR-218,前两者在恶性组中上调,后两者下调。荧光即时定量PCR在22个样本中验证显示,miR.221和miR-675*的差异倍数与基因芯片的结果基本相符。结论通过miRNA芯片初步筛选和荧光即时定量PCR验证,显示miR-221和miR-675*在恶性和交界性GIST中的表达有差异性,提示两者可能与GIST的恶性转化有关,在GIST的生物学行为判断上有潜在的应用价值。 Objective Gastrointestinal stromal tumors (GISTs) have a broad spectrum of biological behaviors ranging from benign, borderline and malignant. This study aimed to screen differentially expressed microRNAs (miRNAs) between malignant and borderline GISTs and to investigate the potential role of miRNAs in the malignant transformation of GISTs. Methods Six GIST samples ineluding borderline tumors (n = 3 ) and malignant tumors (n = 3 ) were collected based on the clinical and pathological characteristics. Total RNA was extracted, followed by miRNA microarray analysis to screen the differentially expressed miRNAs. The most significantly expressed 4 miRNAs were then chosen for further validation by real-time PCR in 22 additional GIST samples. Results Direct comparison of malignant group versus borderline group revealed 14 significantly and differentially expressed miRNAs (P 〈 0. 05, with a fold change of 〈 0. 5 or 〉 2). Five miRNAs were up-regulated and nine were down-regulated in the malignant group. Four miRNAs (miR-221, miR-135b, miR-675* and miR-218) were most siguifieantly and differentially expressed between the two groups. The differential expression of 2 miRNAs (miR-221 and miR-675 * ) were subsequently confirmed with good concordance by real-time PCR. Conclusions The differential miRNA expression profiles between two groups are revealed by miRNA mieroarray assay, and confirmed by real-time PCR. Among differentially expressed miRNAs, miR-221 and miR-675 * might be related to the malignant transformation of GISTs. and have a potential value in predicting biological behavior of CISTs.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2013年第1期20-25,共6页 Chinese Journal of Pathology
基金 国家自然科学基金青年基金(81101809) 上海市卫生局科研课题(2009020)
关键词 胃肠肿瘤 微RNAS 微阵列分析 聚合酶链反应 Gastrointestinal neoplasms MicroRNAs Microarray analysis Polymerase chain reaction
  • 相关文献

参考文献2

二级参考文献56

  • 1贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:73
  • 2詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:86
  • 3Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009, 20 Suppl 4:64-67.
  • 4Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol, 2002, 33(5):459-465.
  • 5Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol, 2005, 29( 1 ) : 52-68.
  • 6Miettinen M, Lasota J. KIT ( CD117 ) : a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol, 2005, 13 (3) :205-220.
  • 7Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol, 2004, 22(18) : 3813-3825.
  • 8Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med, 2006, 130(10) : 1466-1478.
  • 9Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008, 39 (10): 1411-1419.
  • 10DeMatteo RK, Owzar KR, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase Ⅲ trial ACOSOG Z9001. ASCO Annual Meetings Proceedings Part Ⅰ. J Clin Oncol, 2007, 25(18 Suppl) : 10079.

共引文献105

同被引文献105

  • 1Ying-Lung Lin,Jeh-En Tzeng,Chih-Wen Lin.Small gastrointestinal stromal tumor concomitant with early gastric cancer:A case report[J].World Journal of Gastroenterology,2006,12(5):815-817. 被引量:18
  • 2李桂梅,张佃乾,潘素梅,殷正进.胃癌/食道癌合并胃肠间质瘤4例报道[J].临床肿瘤学杂志,2006,11(11):879-880. 被引量:6
  • 3卜君,钱昆,李小军,张明鸣,伍晓汀.胃间质瘤伴胃癌10例的临床分析[J].中华普通外科杂志,2007,22(3):226-226. 被引量:4
  • 4中国胃肠道间质瘤病理共识意见[J].中华病理学杂志,2007,36(10):704-707. 被引量:110
  • 5Duensing S,Duensing A. Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers[J].{H}Biochemical Pharmacology,2010.575-583.
  • 6Downs-Kelly E,Rubin BP. Gastrointestinal stromal tumors:molecular mechanisms and targeted therapies[J].Patholog Res Int,2011.708596.
  • 7Corless CL,Barnett CM,Heinrich MC. Gastrointestinal stromal tumours:origin and molecular oncology[J].{H}Nature Reviews Cancer,2011.865-878.
  • 8师英强;梁小波.胃肠道间质瘤[M]{H}北京:人民卫生出版社,201139-46.
  • 9Hirota S,Isozaki K,Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J].{H}SCIENCE,1998.577-580.
  • 10Corless CL,McGreevey L,Haley A. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size[J].{H}AMERICAN JOURNAL OF PATHOLOGY,2002.1567-1572.

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部